Balancing Life and Death in the Ischemic Brain: SIK and TORC Weigh In  by Gallo, Eduardo F. & Iadecola, Costantino
Neuron
Previewsconsistent with its proposed function as
a decoy or scavenger receptor helping to
shape gradients of CXCL12 that will deter-
mine paths for CXCR4-mediated chemo-
taxis. Clearly therefore, like all seasoned
performers, CXCR7 is comfortable with
a role either as a soloist or dancing a pas
de deux with CXCR4.
Overall, therefore, these two papers
provide a detailed picture of how two che-
mokine receptors cooperate in enabling
the successful migration of a specific
group of neural progenitors in the devel-
oping brain. And, like all important investi-
gations, they also raise numerous issues
and questions. For example, what is the
significance of CXCR7-induced MAP
kinase activation or other types of cell
signaling ? Is such signaling important in
producing CXCR7-mediated effects in
addition to its scavenging function?
Wang et al. (2011) demonstrate that this
type of signaling occurs, but how it influ-
ences the role of CXCR7 is unclear given
the phenotype produced by PTX activa-
tion in migrating neurons. In addition, the
expression of CXCR7 occurs in cellsoutside the developing embryo, including
in cancer cells, which are often viewed as
cells undergoing a dysregulated form of
development. Given the important role of
CXCR4 signaling in the spread of cancer
metastases (Teicher and Fricker 2010),
the functions of proteins like CXCR7 that
can powerfully modify CXCR4 signaling
are clearly of mechanistic and potentially
therapeutic importance. Indeed, it is now
clear that the discovery of CXCR7 has
added an entirely new dimension to our
understanding of how CXCR4 functions
during development and beyond.
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Activation of NMDA receptors during cerebral ischemia triggers signaling pathways that promote both
neuronal death and survival. In this issue of Neuron, Sasaki et al. present evidence for a new endogenous
survival pathway involving the kinase SIK2 and the CREB coactivator TORC1. The powerful neuroprotection
conferred by this pathway has considerable translational potential for stroke therapy.N-methyl-D-aspartate-type glutamate re-
ceptors (NMDARs) are essential for brain
development and function (Citri and
Malenka, 2007; Cohen and Greenberg,
2008), but they also have adark side, play-
ing central roles in neuronal death during
cerebral ischemia and other brain pathol-
ogies (Szydlowska and Tymianski, 2010).
Remarkably, even in such deleterioussettings, NMDARs set in motion powerful
molecular programs that attempt to pro-
tect neurons from the excitotoxic damage
resulting from their activation. Thus,
NMDARactivation enables the expression
of prosurvival genes through the tran-
scription factor cAMP-response element
binding protein (CREB) (Lonze and Ginty,
2002). Although the involvement of CREBin neuroprotection is well established
(Kitagawa, 2007; Lonze and Ginty, 2002),
the molecular mechanisms by which
NMDAR activation promotes CREB-
dependent neuronal survival, while also
promoting cell death, remain poorly un-
derstood. In this issue of Neuron, Sasaki
et al. (2011) shed light on the issueby iden-
tifying ischemia-induced degradation of69, January 13, 2011 ª2011 Elsevier Inc. 3
Figure 1. SIK2 Degradation Provides Neuroprotection after Ischemia
According to Sasaki et al., ischemic neurons utilize a previously unrecognized cytoprotective pathway involving CREB activation through CaMK I/IV, SIK2, and
TORC1 (left), which attempts to counterbalance the deleterious consequences of NMDAR overactivation (right).
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Previewssalt-inducible kinase 2 (SIK2) as a pivotal
step in the activation of CREB-dependent
transcription, an effect involving dephos-
phorylation and nuclear import of the
CREB coactivator transducer of regulated
CREB activity 1 (TORC1) (Figure 1). The
findings establishSIK2andTORC1ascrit-
ical regulators of a novel endogenous
neuroprotective pathway with significant
implications for the treatment of cerebro-
vascular pathologies and other brain
diseases linked to NMDARs.
CREB activation involves multiple
signaling cascades that phosphorylate
CREB to assemble a functional transcrip-
tional complex (Lonze and Ginty, 2002).
Therefore, as they set out to investigate
post-ischemic CREB-dependent tran-
scription, Sasaki et al. first examined
CREB phosphorylation at the well-
described regulatory Ser133 using oxy-
gen glucose deprivation (OGD) in cortical
neuronal cultures, a model that recapitu-
lates key features of ischemia-reperfusion
injury. They uncovered an intriguing tem-
poral dissociation between CREB phos-
phorylation and the upregulation of CRE
activity, as measured using gene reporter
assays, suggestive of a phosphorylation-4 Neuron 69, January 13, 2011 ª2011 Elsevieindependent mechanism of CREB activa-
tion. Consequently, they hypothesized
the involvement of a recently discovered
family of CREB transcriptional coactiva-
tors the TORC family of proteins (Conk-
right et al., 2003; Iourgenko et al., 2003).
TORCs translocate from the cytoplasm
to the nucleus in response to increases
in calcium and cAMP, a step that requires
dephosphorylation (Bittinger et al., 2004;
Screaton et al., 2004). Once in the
nucleus, TORCs bind CREB and promote
CREB-dependent gene expression, an
effect independent of Ser133 phosphory-
lation (Bittinger et al., 2004; Conkright
et al., 2003). Sasaki et al. (2011) found
that, after OGD, TORC1 is dephosphory-
lated and translocated to the nucleus
with a temporal profile that fits well with
the upregulation of CRE activity. Using
constitutively active or dominant-negative
constructs, they provided convincing evi-
dence that TORC1 upregulation or down-
regulation is causally linked to CREB-
dependent gene expression and neuronal
survival after OGD. Although TORC1 has
already been implicated in other CREB-
dependent neuronal functions, such as
synaptic plasticity (Kovacs et al., 2007;r Inc.Zhou et al., 2006), the findings of Sasaki
et al. (2011) establish for the first time
the involvement of TORC1-CREB in an
intrinsic cell survival program triggered
by hypoxia-ischemia.
While dephosphorylation is necessary
for its nuclear translocation, phosphoryla-
tion can sequester TORC in the cytoplasm
(Screaton et al., 2004). To begin to unravel
the factors regulating TORC phosphoryla-
tion during OGD, Sasaki et al. (2011)
focusedonAMPK,SIK1, andSIK2, kinases
known to phosphorylate TORC. They
observed that SIK2 was enriched in
neurons and that its levels did not change
during OGD, much like CRE activity. How-
ever, SIK2 levels were markedly reduced
after OGD in parallel with the increase in
CRE activity and TORC1 dephosphoryla-
tion and nuclear translocation. AMPK and
SIK1 did not exhibit such temporal associ-
ationswithTORC1andCREactivity. These
observations raised the possibility that
SIK2 regulates CREB-dependent tran-
scription through an effect on TORC1
phosphorylation and nuclear translocation.
Consistent with this hypothesis, overex-
pressionofaconstitutivelyactiveSIK2sup-
pressed OGD-induced CRE activity and
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Previewsincreased cell death, whereas an inactive
SIK2 was neuroprotective. Similarly, RNAi
downregulation or pharmacological inhibi-
tion of SIK2 increased CRE activity and
neuronal survival. The demonstration that
SIK2 overexpression reduced CRE activity
in cells cotransfected with a wild-type (WT)
TORC1 construct, but was unable to do so
in the presence of a phosphorylation-resis-
tant mutant of TORC1, clearly established
that these effects of SIK2 were mediated
by TORC1 phosphorylation.
Next, the authors set out to investigate
the upstream mechanisms by which
OGD modulates SIK2 levels and CREB
transcriptional activity. After identifying
CaMK I/IV as potential upstream media-
tors of TORC1-CREB activation, the
authors explored how CaMK I/IV activity
could lead to the reduction in SIK2 levels
induced by OGD. They found that overex-
pression of dominant-negative CaMK I or
CaMK IV constructs prevents the OGD-
induced downregulation of SIK2. In addi-
tion, SIK2 degradation was associated
with an increase in the phosphorylation
of a specific SIK2 residue (Thr484). The
importance of this site for SIK2 degrada-
tion was demonstrated by the fact that
a phosphorylation-resistant Thr484 did
not result in SIK2 degradation. In contrast,
phosphorylation of Ser587, a SIK2 site
also known to negatively regulate TORC
phosphorylation (Katoh et al., 2006), did
not impact SIK2 protein levels. In support
of this conclusion, OGD increased SIK2
Thr484 phosphorylation, but not Ser587
phosphorylation, suggesting that Thr484,
but not Ser587, is an important target of
CaMK I/IV-dependent SIK2 degradation.
Sasaki et al. (2011) provide further
support that SIK2 is a principal regulator
of neuronal survival by generating sik2/
mice and investigating whether neurons
from these mice are protected from
OGD. They found that sik2/ neurons
display higher survival rates than WT
following OGD, an effect associated with
a concomitant increase in TORC1-CREB
activity and induction of prosurvival genes
such as Bdnf and Ppargc-1a. Importantly,
to determine whether SIK2 is involved in
the mechanisms of neuronal death
in vivo, they examined ischemic lesions
in WT and sik2/ mice following occlu-
sion of the middle cerebral artery, a well-
established model of ischemic stroke.
They found that sik2/ mice havereduced ischemic lesions compared with
WT mice and that this neuroprotection is
associated with TORC1 dephosphoryla-
tion only in the ischemic hemisphere of
the sik2/ brains. Consistent with
in vitro results, sik2/ mice were also
found to have increased expression of
CREB-dependent prosurvival genes like
Bdnf and Ppargc-1a, while CREB-inde-
pendent genes are unaffected. However,
sik2/ mice exhibited reduced expres-
sion of the proinflammatory cytokine
tumor necrosis factor (TNF), suggesting
that suppression of post-ischemic inflam-
mation may also contribute to the
observed neuroprotection.
Sasaki et al. (2011) provide extensive
evidence in support of SIK2 as a major
determinant of neuronal survival by its
regulation of CREB-induced gene expres-
sion through a TORC1-dependentmecha-
nism. These results advance the current
understanding of CREB activation in the
context of neuronal survival. Although
CREB phosphorylation has long been
linked to CREB activation in various
aspects of neuronal function, including
neuroprotection (Lonze and Ginty, 2002),
this study highlights the functional rele-
vance of an alternative mechanism
present in neurons that activates CREB.
Given the complexity of neuronal CREB
activation, future studies could be aimed
at further elucidating the mechanisms
regulating TORC1. For example, synaptic
activity can simultaneously activate a
number of signaling cascades that lead
toCREB-dependent gene expression (Co-
hen andGreenberg, 2008). Understanding
the contribution of each of these different
pathways to TORC1 activation may help
unravel thebiological advantageconferred
by utilizing multiple means to promote the
expression of CREB-dependent genes.
Moreover, addressing the signaling events
involved in the dephosphorylation of
TORC1 and SIK2 may also reveal new
regulatory mechanisms. Because the
signaling pathways described in this study
were demonstrated to be downstream of
synaptic NMDARs, these findings are
highly relevant to other neural functions
involving NMDAR-induced gene expres-
sion and to pathological states mediated
by these receptors. In addition, the attenu-
ation in TNF observed in sik2/ mice
raises the possibility that SIK2 is also
involved in post-ischemic inflammation.NeuronFurther studies exploring the mechanisms
underlying this effect would be of interest
because they might unveil a previously
unrecognized link between SIK proteins
and inflammatory signaling.
The findings of the present study are
particularly relevant to the pathobiology
of cerebral ischemia-reperfusion and to
strategies to protect the brain from the
devastating consequences of ischemic
stroke. Treatments targeting theNMDARs
and other pathogenic factors in the
ischemic cascade have not been
successful in stroke clinical trials (Gins-
berg, 2009). While the issues surrounding
these disappointing results are still being
debated, it has also become clear that
therapeutic approaches mimicking en-
dogenous neuroprotective strategies
have a great translational potential, but
are relatively unexplored (Moskowitz
et al., 2010). By identifying and character-
izing a series of novel mediators in a
critical, yet poorly understood, neuropro-
tective signaling cascade (Figure 1), Sa-
saki et al. (2011) have provided valuable
insight into new targets for therapeutic
ischemic stroke and other pathologies
involving NMDARs. Therapeutic ap-
proaches targeting the SIK2-TORC1-
CREB pathway using small molecules or
other clinically applicable pharmacolog-
ical tools have great potential for stroke
treatment and are eagerly awaited.REFERENCES
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Heterodimerization of G protein-coupled receptors has become increasingly recognized as a valuable mech-
anism to increase receptor diversity. Heterodimers have been observed in the opioid receptor family, but one
of the most intriguing is that formed between m-opioid and d-opioid receptors. In this issue of Neuron, He
et al. present evidence further implicating these heterodimers in morphine tolerance.Understanding opioid tolerance has long
been a goal in the opioid field. Recent
years have revealed many new and ex-
citing observations regarding the under-
lying the processes. These involve many
different and unrelated mechanisms,
making the integration of these pathways
very difficult. Opioid tolerance is the
diminished response seen with chronic
administration of a drug or, put another
way, the need to progressively increase
drug doses to maintain a response. Toler-
ance is the final common pathway for
a wide range of divergent mechanisms,
much like a tug of war with many different
people pulling on the same rope. Each is
contributing to the final effort and the
loss of any one of them can have a similar
effect. In this issue of Neuron, He et al.
(2011) describe results that support the
concept that one aspect of tolerance is
mediated through m/d heterodimers and
present a mechanism explaining the
ability of d-opioid receptor (DOR) antago-
nists to prevent tolerance to morphine.
Morphine tolerance involves many
distinct systems and can be influenced in
many ways. The first was put forward by
Collier (1980), who proposed what he
referred to as a ‘‘hypertrophy of the cyclicAMP system.’’ This was followed by the
identification of the role of other neuro-
transmitter systems, as illustrated by
the loss of morphine tolerance with
blockade of the N-methyl-D-aspartate
(NMDA) receptor/nitric oxide cascade.
Many classes of NMDA receptor antago-
nists can effectively prevent or reverse
morphine tolerance (Trujillo and Akil,
1991), as can inhibition of nitric oxide
synthase (Kolesnikov et al., 1997). The
importance of dispositional issues was
established by studies on P-glycoprotein
(King et al., 2001). Chronic administration
of morphine upregulates P-glycoprotein,
which in turn decreases morphine
penetration into the brain. Knocking out
Pgp prevents morphine tolerance. Most
recently, investigators have explored
receptor trafficking (Von Zastrow, 2010)
and suggested a role for m-opioid/d-opioid
receptor (MOR/DOR)heterodimers (Gupta
et al., 2010). These various differentmech-
anisms are not exclusive and all probably
contribute to the overall response.
The role of d systems in morphine toler-
ance was first proposed by Takemori and
coworkers (Abdelhamid et al., 1991), who
showed that the DOR antagonist naltrin-
dole prevents morphine tolerance. Theimportance of DORs was confirmed by
studies in DOR knockout mice and anti-
sense downregulation models that also
revealed the loss of morphine tolerance.
In the current paper by He and coworkers
(He et al., 2011), the authors find that
spinal delivery of the d ligand deltorphin I
diminished morphine actions, consistent
with an inhibitory modulation of morphine
analgesia. The opioid field has long had
controversies and data that appear
contradictory, and the role of d systems
in morphine action is no exception. Soon
after their discovery, enkephalins, endog-
enous DOR ligands, were shown to be
potent analgesics given either spinally or
supraspinally. Furthermore, Porreca and
coworkers (Porreca et al., 1987) demon-
strated that d ligands given supraspinally,
but not spinally, potentiated morphine
analgesia in naive and tolerant mice.
Thus, d drugs can both potentiate and
diminish morphine analgesia. A number
of potential explanations for these con-
flicting results are possible, including
the site of action (i.e., spinal versus
supraspinal), since potentiation was pre-
viously seen only supraspinally while the
decreased effect in the current paper
was documented at the spinal level.
